Optimizing HBV Prevention When Switching to Long-Acting Cabotegravir/Rilpivirine.
2026-04-03, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America (10.1093/cid/ciag218) (online)Ana González-Cordón, Alberto Foncillas, Montserrat Laguno, Juan Ambrosioni, Josep Mallolas, and Lorena de la Mora (?)
This article has not yet been included in any curations.
Comments
There are no comments on this article yet.
You need to login or register to comment.